Medicare Enrolled
Dr. Vidal Espeleta, M.D.
Pulmonary Disease · Laguna Hills, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Espeleta from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Espeleta?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Espeleta
Dr. Vidal Espeleta is a pulmonary disease specialist in Laguna Hills, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Espeleta performed 2,850 Medicare services across 1,562 unique beneficiaries.
Between the years covered by Open Payments, Dr. Espeleta received a total of $9,668 from 50 pharmaceutical and/or device companies across 371 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Espeleta is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 13% volume in CA
$9,668 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,850
Medicare services
Top 13% in CA for pulmonary disease
1,562
Unique beneficiaries
$96
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~150 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
909 | $100 | $163 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
517 | $101 | $175 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
497 | $177 | $500 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
113 | $52 | $76 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
113 | $0 | $25 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
112 | $35 | $175 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
112 | $29 | $165 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
111 | $8 | $35 |
| Lung volume measurement test A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs. |
110 | $13 | $59 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
110 | $50 | $76 |
| New patient office visit, complex (60-74 min) | 80 | $170 | $331 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
31 | $145 | $340 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
18 | $101 | $559 |
| Additional 30 minutes of critical care This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period. |
17 | $89 | $196 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$9,668
Total received (2018-2024)
Avg $1,381/year across 7 years
Top 17% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
371
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,652 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$16 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,313
2023
$1,947
2022
$1,781
2021
$853
2020
$661
2019
$1,584
2018
$1,529
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$542
Pulmonx Corporation
$178
Boehringer Ingelheim Pharmaceuticals, Inc.
$83
INTUITIVE SURGICAL, INC.
$70
AstraZeneca Pharmaceuticals LP
$55
GENZYME CORPORATION
$46
Actelion Pharmaceuticals US, Inc.
$35
Regeneron Healthcare Solutions, Inc.
$34
HARMONY BIOSCIENCES LLC
$31
United Therapeutics Corporation
$29
Arjo Inc.
$29
Shionogi Inc
$29
Grifols USA, LLC
$27
ABBVIE INC.
$27
Gilead Sciences, Inc.
$24
Vifor Pharma, Inc.
$20
Philips North America LLC
$17
Baxter Healthcare
$17
Insmed, Inc.
$17
Top 3 companies account for 61.2% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$2,349
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,530
AstraZeneca Pharmaceuticals LP
$986
Intuitive Surgical, Inc.
$665
Inari Medical, Inc.
$409
Philips Electronics North America Corporation
$374
Pulmonx Corporation
$230
Janssen Pharmaceuticals, Inc
$225
Sunovion Pharmaceuticals Inc.
$193
Grifols USA, LLC
$178
Baxter Healthcare
$171
Insmed, Inc.
$148
JAZZ PHARMACEUTICALS INC.
$145
Harmony Biosciences LLC
$135
Inspire Medical Systems, Inc.
$133
Veran Medical Technologies, Inc.
$132
Regeneron Healthcare Solutions, Inc.
$131
Ethicon Inc.
$123
Mylan Specialty L.P.
$106
BIOTRONIK INC.
$100
Genentech USA, Inc.
$97
Shionogi Inc
$95
GENZYME CORPORATION
$94
INTUITIVE SURGICAL, INC.
$70
Merck Sharp & Dohme Corporation
$66
HARMONY BIOSCIENCES LLC
$60
Advanced Respiratory, Inc
$59
Fisher & Paykel Healthcare Inc
$57
Actelion Pharmaceuticals US, Inc.
$54
United Therapeutics Corporation
$52
PORTOLA PHARMACEUTICALS, INC.
$49
Axsome Therapeutics, Inc.
$46
Amgen Inc.
$35
Ambu Inc.
$29
Mallinckrodt Hospital Products Inc.
$29
Arjo Inc.
$29
ABBVIE INC.
$27
Shire North American Group Inc
$26
La Jolla Pharmaceutical Company
$25
Gilead Sciences, Inc.
$24
Otsuka America Pharmaceutical, Inc.
$22
ADVANCED RESPIRATORY, INC
$21
Vifor Pharma, Inc.
$20
Paratek Pharmaceuticals, Inc.
$20
Allergan, Inc.
$20
Philips North America LLC
$17
Circassia Pharmaceuticals Inc
$17
Electromed, Inc.
$16
Merck Sharp & Dohme LLC
$14
Melinta Therapeutics, Inc.
$12
Top 3 companies account for 50.3% of all-time payments
Associated products mentioned in payments ›
(4575) DreamStation CPAP Cell · (8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ANDEXXA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Arikayce · BEVESPI AEROSPHERE · BEVYXXA · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHARTIS CATHETER · DUPIXENT · Da Vinci Surgical System · DreamStat Cpap Auto · Dymista · Edora · Esbriet · FASENRA · FISHER & PAYKEL HEALTHCARE · FLOWTRIEVER CATHETER · Fetroja · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Monarch Airway Clearance System · Hillrom - Vest System Model 105 Home Care · Inspire Upper Airway Stimulation System · LONHALA MAGNAIR · Life 2000 Ventilation System · Monarch Platform · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · Perforomist · Prolastin-C Liquid · Respiratoriy Care Undiv · S · S&RC Und · SAMSCA · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · Spin · Sunosi · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · The VitalCough System · Trilogy 100 · Utibron · Vabomere · WAKIX · Wakix · XARELTO · XYWAV · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
85
Per 100K population
2.7
County median income
$113,702
Nearest hospital
MEMORIALCARE SADDLEBACK MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Espeleta is a clinical cardiology specialist, with above-average Medicare volume (top 13% in CA), with low-engagement industry engagement in the top 17% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Espeleta experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Espeleta performed 909 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Espeleta receive payments from pharmaceutical companies?
Yes. Dr. Espeleta received a total of $9,668 from 50 companies across 371 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Espeleta's costs compare to other pulmonary diseases in Laguna Hills?
Dr. Espeleta's average Medicare payment per service is $96. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Espeleta) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Laguna Hills
Browse pulmonary diseases in Laguna Hills ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology